1-3). Antiphospholipid syndrome

Internal Medicine

Volumn 38, Issue 2, 1999, Pages 170-173

  Ichikawa, Kenji ^a   Tsutsumi, Akito ^a   Matsuura, Eiji ^b   Koike, Takao ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anticardiolipin antibody; Lupus anticoagulant; 2 glycoprotein I, phage display random peptide library

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; GLYCOPROTEIN; PHOSPHOLIPID ANTIBODY;

AMINO ACID SEQUENCE; ANTIPHOSPHOLIPID SYNDROME; CHEMISTRY; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; PROTEIN TERTIARY STRUCTURE; REVIEW;

AMINO ACID SEQUENCE; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; GLYCOPROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY;

EID: 0033072849     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.38.170     Document Type: Article

References (23)

1. Harris EN, Gharavi AE, Boey ML, et al. Anti-cardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet ii: 1211-1214, 1983.
2. Harris EN, Asherson RA, Gharavi AE, Morgan SH. Derue G, Hughes GR. Thrombocytopenia in SLE and related autoimmune disorders: Association with anticardiolipin antibody. Br J Haematol 59: 227-230, 1985.
3. Levine SR, Welch KMA. Cerebrovascular Ischemia associated with lupus anticoagulant. Stroke 18: 257-263, 1986.
4. Asherson RA, Khamashta MA, Gil A, et al. Cerebrovascular disease and anti-phospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholiped syndrome. Am J Med 86: 391-399, 1989.
5. Hamsten A, Norberg R, Bjorkholm M, de Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction. An association with recurrent cardiovascular events. Lancet i: 113-116, 1986.
6. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine 68: 366-374, 1989.
7. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 19: 508-512, 1992.
8. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor (s) and differential diagnosis of autoimmune disease. Lancet 336: 177-178, 1990.
9. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87: 4120-4124, 1990.
10. Galli M, Confurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335: 1544-1547, 1990.
11. Matsuura E, Igarashi M, Igarashi M et al. Molecular definition of human β2-glycoprotein I (β2-GPI) by cDNA cloning and inter-species differences of β-GPI in alternation of anticardiolipin binding. Int Immumol 3: 1217-1221, 1991.
12. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interaction with an oxygen modified solid phase surface. J Exp Med 179: 457-462, 1994.
13. Ichikawa K, Khamashita MA, Koike T, Matsuura E, Hughes GRV. β2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 37: 1453-1461, 1994.
14. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 66: 629-632, 1991.
15. Oosting JD, Dereksen RH, Entjes HT, Bouma BN, de Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of β2-glycoprotein I. Thromb Haemost 67: 499-502, 1992.
16. Hunt J, Krilis S. The fifth domain of β2-glycoprotein I contain a phospholipid binding site (Cys281-Cyc288) and region recognized by anticardiolipin antibodies. J Immunol 152: 653-659, 1994.
17. Igarashi M, Matsuura E, Igarashi Y, et al. Human β2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by baculovirus system. Blood 87: 3262-3270, 1996.
18. Nimpf J, Wurm H, Kostner GM. Interaction of β2-glycoprotein I with human blood platelets: Influence upon the ADP-induced aggregation. Thromb Haemost 54: 397-401, 1985.
19. Schousboe I. β2-glycoprotein I: A plasma Inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 66: 1086-1091, 1985.
20. Nimpf J, Bevers EM, Bomans PHH, et al. Prothrombinase activity of human platelets is inhibited by β2-glycoprotein I. Biochem Biophys Acta 884: 142-149, 1986.
21. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107: 569-573, 1997.
22. Norman DG, Barlow PN, Baron M, Day AJ, Sim RB, Campbell ID. Three-dimensional structure of a complement control protein module in solution J Mol Biol 219: 717-725, 1991.
23. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 249: 386-390, 1990.